US Digital Therapeutics Growth Opportunities

US Digital Therapeutics Growth Opportunities

Transformational Growth in New Business Models After COVID-19

RELEASE DATE
23-Jul-2021
REGION
North America
Research Code: K5CF-01-00-00-00
SKU: HC03434-NA-MT_25609
$4,950.00
In stock
SKU
HC03434-NA-MT_25609
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Patients with long-term chronic conditions and rare diseases are looking for safe, novel, and evidence-based digital treatments in their pursuit to reduce dosages and reverse triggers of adverse events. Payers and providers are looking for legitimate alternatives to expensive medication for their patient population. Life sciences (LS) companies are trying to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery in the long run.

Digital therapeutics (DTx) companies are working with LS to diversify their pipelines by adding new indications addressing unmet needs. Most digital health technologies have long suffered for not being able to systematically prove clinical efficacy of their solutions via peer-reviewed reports. Thus, they have never secured the unique distinction of being a regulated and “prescription-grade” digital treatment plan that guarantees improved patient outcomes and comprehensive reimbursement at the same time.

Convergence of biopharma & healthtech, traditionally two different IT workflows, will play a major role in the shift toward integrated patient management. Patient-centric digital health vendors have strived for a business model that allows physicians to recommend their products, patients to use them for a defined period of time (without fail), caregivers to monitor outcomes 24/7, and payers to reimburse the cost of usage. DTx companies partnering with LS companies provide the best way of getting access to patients for scalability, apart from risk-sharing agreements.

DTx solutions are considered as legitimate alternatives to traditional pharmacotherapy. These solutions are comprehensively regulated and they are granted the prescription status by various national or state-level regulatory agencies (FDA, NHS, and CE) based on their reported evidence of improved clinical outcomes for a defined patient population.

Globally, the US also remains a key market for growth for two important reasons, which are a higher reimbursement rate (20% to 30% higher than rest of the world) per subscriber per month, and early adoption by payers, providers, and life sciences companies.

Payers remain the top end-users in terms of their contribution to the global DTx revenue. They estimate to reimburse 65% to 70% of the US market revenue via various value-based payment plans that patients will be either auto-eligible or subscribed to (due to reference from physicians or formulary decision makers).

Life sciences’ contribution to the US DTx market will grow the fastest (at CAGR of 52.6%) amongst all end-users. This is due to DTx’s ability to report real-world evidence at scale, an essential requirement for managing disease progression, identifying new bio markers, and recruiting patients optimally for driving favorable clinical trial outcomes.

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

Strategic Imperatives

The Impact of the Top Three Strategic Imperatives on Digital Therapeutics

The State and Outlook of per Capita Healthcare Spending in US

With Rapid Global Adoption of DTx Solutions, Large-scale Commercialization is Expected Soon

Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Environment

Growth Environment (continued)

Digital Therapeutics Scope of Analysis

Introduction of Digital Therapeutics Solutions

Introduction of Digital Therapeutics Solutions (continued)

Application and End-user Segmentation

Key Competitors in US Digital Therapeutics

Growth Drivers for US Digital Therapeutics Market

Growth Restraints for US Digital Therapeutics Market

Key Growth Metrics for US Digital Therapeutics Market

Regulatory Outlook of US Digital Therapeutics Market, 2020–2021

Types of Digital Therapeutics Solutions by Therapeutics Areas

Reimbursement Trends in US Digital Therapeutics Market, 2020–2021

Market Trends by Key Application Areas, Disease Management

Market Trends by Key Application Areas, Wellness and Behavior Management

Market Trends by Key Application Areas, Outcomes Analytics

Inconsistent Results Prioritize Pharmaceutical Investment in Digital Therapeutics

Forecast Assumptions, US Digital Therapeutics Market

Revenue Forecast, US Digital Therapeutics Market

Revenue Forecast by Applications, US Digital Therapeutics Market

Business Model Description

Business Model Description (continued)

Competitive Environment, US Digital Therapeutics Market

Competitive Profiles

Competitive Profiles (continued)

Competitive Profiles (continued)

Key Growth Metrics for US Provider Digital Therapeutics Market

Revenue Forecast, US Provider Digital Therapeutics Market

Revenue Forecast Analysis, US Provider Digital Therapeutics Market

Key Growth Metrics for US Payer Digital Therapeutics Market

Revenue Forecast, US Payer Digital Therapeutics Market

Revenue Forecast Analysis, US Payer Digital Therapeutics Market

Key Growth Metrics for US Life Sciences Digital Therapeutics Market

Revenue Forecast, US Life Sciences Digital Therapeutics Market

Revenue Forecast Analysis, US Life Sciences Digital Therapeutics Market

Growth Opportunity 1: Prescription-grade SaMD that Auto-upgrades Treatment Plans Based on Patient’s Bio-marker Reading for Dosage Optimization

Growth Opportunity 1: Prescription-grade SaMD that Auto-upgrades Treatment Plans Based on Patient’s Bio-marker Reading for Dosage Optimization (continued)

Growth Opportunity 2: DTx-related PaaS Capability that Specializes in Multiple Therapeutic Areas to Help IT Companies Build Capabilities at Scale

Growth Opportunity 2: DTx-related PaaS Capability that Specializes in Multiple Therapeutic Areas to Help IT Companies Build Capabilities at Scale (continued)

Growth Opportunity 3: DTx to Support Evidence-based Treatment and Medication Adherence for Patients, Providers, and Payers Alike

Growth Opportunity 3: DTx to Support Evidence-based Treatment and Medication Adherence for Patients, Providers, and Payers Alike (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

Patients with long-term chronic conditions and rare diseases are looking for safe, novel, and evidence-based digital treatments in their pursuit to reduce dosages and reverse triggers of adverse events. Payers and providers are looking for legitimate alternatives to expensive medication for their patient population. Life sciences (LS) companies are trying to enhance patients treatment experiences and find new biomarkers that aid drug discovery in the long run. Digital therapeutics (DTx) companies are working with LS to diversify their pipelines by adding new indications addressing unmet needs. Most digital health technologies have long suffered for not being able to systematically prove clinical efficacy of their solutions via peer-reviewed reports. Thus, they have never secured the unique distinction of being a regulated and “prescription-grade” digital treatment plan that guarantees improved patient outcomes and comprehensive reimbursement at the same time. Convergence of biopharma & healthtech, traditionally two different IT workflows, will play a major role in the shift toward integrated patient management. Patient-centric digital health vendors have strived for a business model that allows physicians to recommend their products, patients to use them for a defined period of time (without fail), caregivers to monitor outcomes 24/7, and payers to reimburse the cost of usage. DTx companies partnering with LS companies provide the best way of getting access to patients for scalability, apart from risk-sharing agreements. DTx solutions are considered as legitimate alternatives to traditional pharmacotherapy. These solutions are comprehensively regulated and they are granted the prescription status by various national or state-level regulatory agencies (FDA, NHS, and CE) based on their reported evidence of improved clinical outcomes for a defined patient population. Globally, the US also remains a key market for growth for two important reasons, which are a higher reimbursement rate (20% to 30% higher than rest of the world) per subscriber per month, and early adoption by payers, providers, and life sciences companies. Payers remain the top end-users in terms of their contribution to the global DTx revenue. They estimate to reimburse 65% to 70% of the US market revenue via various value-based payment plans that patients will be either auto-eligible or subscribed to (due to reference from physicians or formulary decision makers). Life sciences contribution to the US DTx market will grow the fastest (at CAGR of 52.6%) amongst all end-users. This is due to DTxs ability to report real-world evidence at scale, an essential requirement for managing disease progression, identifying new bio markers, and recruiting patients optimally for driving favorable clinical trial outcomes.
More Information
No Index No
Podcast No
Author Koustav Chatterjee
Industries Healthcare
WIP Number K5CF-01-00-00-00
Is Prebook No
GPS Codes 9564-B1,9600-B1,9612-B1